MedTrace Logo

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

NCT01165216 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-07-22

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study was to establish the recommended dose of ipilimumab administered in combination with paclitaxel and carboplatin in Japanese patients with nonsmall-cell lung cancer.

Conditions

Interventions

DRUG

Ipilimumab, 3 mg

Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles

DRUG

Ipilimumab, 10 mg

IV injection, administered every 3 weeks for up to 6 cycles

DRUG

Paclitaxel

IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles

DRUG

Carboplatin

IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Japan

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165216 on ClinicalTrials.gov